ライフサイエンスコーパス: allograft failure

1 y outcomes included death and death-censored allograft failure.

2 ejection (ABMR) is a leading cause of kidney allograft failure.

3 er, prolonged cold storage can contribute to allograft failure.

4 e analyses for the primary outcome of kidney allograft failure.

5 the former also contribute significantly to allograft failure.

6 mg), five patients (55.5%) experienced renal allograft failure.

7 ry T cells that could favorably prevent late allograft failure.

8 ogic lesions, and a risk predictor of kidney allograft failure.

9 mpered by recurrent infection and subsequent allograft failure.

10 nd progression of the disease often leads to allograft failure.

11 ther a linear nor nonlinear association with allograft failure.

12 study the association of BP and the time to allograft failure.

13 ar immunity is the reputed mechanism of lung allograft failure.

14 or death censored graft survival and chronic allograft failure.

15 ased risk for humoral sensitization or renal allograft failure.

16 Chronic rejection is now the major cause of allograft failure.

17 y disease is the major cause of late cardiac allograft failure.

18 factor for the development of chronic renal allograft failure.

19 rstood process and the primary cause of late allograft failure.

20 sked whether aPA are a risk factor for early allograft failure.

21 ent for the prevention of intrahepatic islet allograft failure.

22 t an ideal agent for the prevention of islet allograft failure.

23 disease were identified as risk factors for allograft failure.

24 are an important risk factor for early renal allograft failure.

25 h acute vascular rejection and early cardiac allograft failure.

26 ntify those patients at high risk for future allograft failure.

27 not prevent progressive chronic-type cardiac allograft failure.

28 t elements that ultimately result in chronic allograft failure.

29 iation of prerenal and intrinsic acute renal allograft failure.

30 important role in the development of chronic allograft failure.

31 been hypothesized to be one cause of chronic allograft failure.

32 ephropathy is associated with a high rate of allograft failure.

33 bular atrophy (IF/TA), is a leading cause of allograft failure.

34 ft arteriosclerosis (GA), the major cause of allograft failure.

35 e the primary outcomes of death and death or allograft failure.

36 span, defined as the time free from death or allograft failure.

37 ding to rapidly progressive and irreversible allograft failure.

38 rejection remains the major cause of corneal allograft failure.

39 associated with increased risk of long-term allograft failure.

40 e strongly and independently associated with allograft failure.

41 ing centers to reduce costs and incidence of allograft failure.

42 olic hypertension (SHT) are risk factors for allograft failure.

43 ion therapy abolishes the disparity in renal allograft failure.

44 and microvasculature injury were at risk of allograft failure.

45 ospitalization with fever within 6 months of allograft failure.

46 between delayed graft function and long-term allograft failure.

47 ospitalization with fever within 6 months of allograft failure.

48 linical transplantation contributes to islet allograft failure.

49 tment of dnDSA-positive patients can prevent allograft failure.

50 ch may lead to chronic humoral rejection and allograft failure.

51 f anti-HLA antibodies plays a role in kidney-allograft failure.

52 e of chronic rejection, the primary cause of allograft failure.

53 r of alloantibody sensitization after kidney allograft failure.

54 emodeling, which may be one cause of chronic allograft failure.

55 el at retransplant and subsequent pancreatic allograft failure.

56 initial episodes of Gram-negative BSI before allograft failure.

57 tion and a lower risk of death, but not with allograft failure.

58 The primary endpoint was 90-day allograft failure.

59 lated that autoantibodies may play a role in allograft failure.

60 detect clinically significant differences in allograft failure.

61 esponses are responsible for the majority of allograft failures.

62 jects including 125 cases of intrinsic acute allograft failure, 27 prerenal graft failures, 118 patie

63 d 170 AA) eliminated the racial disparity in allograft failure (5.7% vs 9.4%, P = 0.8248, hazard rati

64 Early allograft failure accounts for approximately 25% of deat

65 ith delayed graft function but not all-cause allograft failure (adjusted hazard ratio 1.01, 95% CI 0.

66 Identification of risk factors for renal allograft failure after an episode of acute antibody-med

67 egression model to identify risk factors for allograft failure after C4d+ acute AMR.

68 in the TLR2 gene have increased the risk of allograft failure after liver transplantation for chroni

69 or the predisposition of patients to develop allograft failure after liver transplantation for chroni

70 ctors that predispose patients to pancreatic allograft failure after renal retransplantation.

71 e of recipient metabolic rate to the rate of allograft failure among 239 recipients of cadaveric rena

72 ce with medication is a major cause of renal allograft failure among adult renal transplant patients.

73 mate the effect of ESA hyporesponsiveness on allograft failure and all-cause mortality.

74 AV) remains the most prevalent cause of late allograft failure and cardiac mortality.

75 = 3237) was associated with greater risks of allograft failure and death compared with a CNI-based re

76 in a significantly increased risk of kidney allograft failure and death.

77 Addition of donor PLNC prevent islet allograft failure and leads to recipient chimerism for a

78 R2 Arg753Gln polymorphism is associated with allograft failure and mortality after liver transplantat

79 hazard ratios (95% confidence interval) for allograft failure and mortality after transplantation we

80 is associated with an increased incidence of allograft failure and mortality, the results of this stu

81 ansplantation ESA response and its effect on allograft failure and mortality.

82 review of 29 consecutive patients with renal allograft failure and nephrectomy.

83 significant risk factor for kidney and liver allograft failure and patient mortality.

84 20-3.89, P=0.01), but the rates of recipient allograft failure and recipient mortality across donor B

85 and 2006 and assessed the effects of RLN on allograft failure and recipients' survival.

86 hesis that podocyte depletion contributes to allograft failure and reduced allograft half-life.

87 efined as duration of dialysis between first allograft failure and second transplantation, and clinic

88 omes in 300 consecutive patients with kidney allograft failure and survival of more than 30 days afte

89 ted hazard ratios (HRs) for death, all-cause allograft failure, and allograft failure excluding death

90 ariate analysis were performed using chronic allograft failure as the outcome of interest.

91 or = 20%) were significantly associated with allograft failure at 5 years.

92 th IFN-gamma:IL-5 ratios > or = 15 developed allograft failure at 6 months (sensitivity 100%, specifi

93 to 12 hr showed an adjusted absolute risk of allograft failure at 90 days of 17.3% (odds ratio 1.84),

94 ged cold ischemia interact to increase liver allograft failure at 90 days.

95 Excluding early allograft failure because of primary graft nonfunction o

96 diagnosis and 21 days later, died from liver allograft failure because of recurrent lymphoma.

97 208 renal transplant recipients with primary allograft failure between 1985 and 1995 were followed fr

98 related relative cost with observed/expected allograft failure between centers, excluding small cente

99 d returned to long-term dialysis after renal allograft failure between January 1994 and December 2004

100 of the tempo and intensity of chronic renal allograft failure, but also a potent modulator of fundam

101 We conclude that AMR may cause allograft failure, but that the diagnosis requires a mul

102 adjustment for DGF, the within-pair ORs for allograft failure by 1 yr were 1.92 (95% CI 1.33 to 2.77

103 the relative risk for development of chronic allograft failure (CAF) by 27% (risk ratio [RR] 0.73, P<

104 factor for the development of chronic renal allograft failure (CAF), which is a major cause of late

105 secondary to acute rejection (AR) or chronic allograft failure (CAF).

106 pendent effect on the development of chronic allograft failure (CAF).

107 ronic vascular rejection, a leading cause of allograft failure, can be inhibited by pravastatin in a

108 CAV) is the preeminent cause of late cardiac allograft failure characterized histologically by concen

109 e similar longitudinal risk of mortality and allograft failure compared with tacrolimus-based regimen

110 In the event of a composite allograft failure, damage to the recipient tissues may m

111 All subjects were followed until allograft failure, death, or December 31, 1992, whicheve

112 Time to allograft failure (defined as death, return to dialysis,

113 were death censored graft survival, chronic allograft failure, delayed graft function, and acute rej

114 de novo collapsing glomerulopathy leading to allograft failure developed in the third patient, who ha

115 Three died from allograft failure due to recurrent HCV.

116 d with a 52 percent reduction in the risk of allograft failure during the first year after transplant

117 The reduction in the rate of allograft failure during the first year was attenuated w

118 for death, all-cause allograft failure, and allograft failure excluding death as a cause (competing

119 y], but ADPKD associated with a lower HR for allograft failure excluding death as a cause [0.85 (0.79

120 .34 to 1.81), respectively, and with HRs for allograft failure excluding death as a cause of 1.20 (1.

121 virus, a human polyomavirus associated with allograft failure following kidney transplantation.

122 The adjusted relative risk (RR) of allograft failure for a 15-kg increase in recipient body

123 The relative rate of allograft failure for patients who received a transplant

124 d with a lower multivariate adjusted risk of allograft failure from any cause including death (hazard

125 en associated with increasing rates of renal allograft failure from cadaveric donors, independent of

126 s associated with recovery or progression to allograft failure from chronic rejection (CR) were studi

127 inotransferase (P<0.03) were associated with allograft failure from CR.

128 The relationship between cost and kidney allograft failure has not been fully investigated in the

129 of transplant recipients after primary renal allograft failure has not been well studied.

130 nts, infection/multisystem organ failure and allograft failure (hazard ratio = 1.08 per year incremen

131 eys with WIT>48 minutes had a higher risk of allograft failure (hazard ratio, 1.23; 95% CI, 1.07 to 1

132 an estimate of the BKPyV-associated risk of allograft failure (hazards ratio = 2.01) without confoun

133 eatment was associated with a higher risk of allograft failure (hazards ratio, 2.01; 95% confidence i

134 ationship between the cause of primary renal allograft failure, hemoglobin A1c (HbA1c) or fasting C-p

135 ed the significance of hypertension in renal allograft failure; however, these studies have been comp

136 P<0.01) and no difference in death-censored allograft failure (HR 1.09, P=0.62), whereas recipients

137 Recurrent disease increased the risk of allograft failure (HR 2.36, 95% CI 1.28-4.32, P=0.0056).

138 [95% CI], 1.03 to 1.26; P<0.01) and death or allograft failure (HR, 1.18; 95% CI, 1.09 to 1.28; P<0.0

139 Allograft failure in African-Americans remains higher th

140 levels of CRP are associated with subsequent allograft failure in cardiac transplant recipients.

141 t risk factor for the development of chronic allograft failure in Caucasians (RR 1.29 for ages 50-64,

142 ate cohort predicts death-censored long-term allograft failure in DSA+ patients regardless of MFI, an

143 with more aggressive recurrent HCV and early allograft failure in HCV-positive liver transplant recip

144 , progression, and severity of chronic renal allograft failure in patients with elevated serum creati

145 for both humoral allosensitization and renal allograft failure in situations of HLA-Bw4 incompatibili

146 157, 67 whites and 90 AA) had lower rates of allograft failure in the absence of AL induction (14.9%

147 risk models were used to assess for risk of allograft failure in the presence of death as a competin

148 There were six renal allograft failures in the nonsensitized group but none i

149 The risk of allograft failure increased 36% for every 2-fold increas

150 irmed that there is an association of BP and allograft failure independent of renal function.

151 th acute-on-chronic liver failure or primary allograft failure is a preferable candidate for this pro

152 Finally, death due to allograft failure is associated with the presence of de

153 Prevention of acute allograft failure is consistent with known immunomodulat

154 The pathophysiology of allograft failure is not fully understood.

155 ONALE: The predominant cause of chronic lung allograft failure is small airway obstruction arising fr

156 tion, which is the most common cause of late allograft failure, is in part caused by an ongoing immun

157 hough perioperative CD154 blockade prevented allograft failure, it did not reduce allograft vasculopa

158 culate the cumulative risk of death-censored allograft failure may overestimate the risk of failure e

159 were accounted for in the adjusted cost and allograft failure models, they are unlikely to explain t

160 lure during follow-up, accounting for 69% of allograft failures occurring after 2.5 years after trans

161 1 reached the combined secondary endpoint of allograft failure or death (9.4 vs. 35.5%, P=0.01); in a

162 dently associated with allograft loss due to allograft failure or death (hazard ratio [HR], 2.52; 95%

163 survival benefit in the combined endpoint of allograft failure or death.

164 iously hemodialyzed patients did not predict allograft failure or success (P=0.3766).

165 after kidney transplantation and may lead to allograft failure or urosepsis.

166 ents older than 70 years had a lower risk of allograft failure (P < 0.01 for each comparison); result

167 o graft failure, CRP level was predictive of allograft failure (P:=0.003).

168 he time of transplantation experienced early allograft failure (P=0.0022).

169 er allografts may increase cold ischemia and allograft failure, particularly with livers from older d

170 t 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95%

171 methodology, can offer insight into chronic allograft failure phenotypes and provide prognostic info

172 between relative cost and observed/expected allograft failure (r = 0.096, P = 0.22).

173 in mortality (HR 0.98, P=0.83) but a higher allograft failure rate (HR 1.93, P<0.01).

174 centers with higher than expected costs and allograft failure rates (lower performing) and centers w

175 ients with IgAN or vasculitis had the lowest allograft failure rates.

176 is associated with a small increased risk of allograft failure regardless of open or laparoscopic app

177 ity (3.7% vs 3.8%; P = 0.788), 1-year kidney allograft failure/rejection (16.7% vs 16.8%; P = 0.897),

178 for mortality, rehospitalization and kidney allograft failure/rejection for weekend (defined as Frid

179 ar risk for rehospitalization, mortality, or allograft failure/rejection.

180 for 1-year mortality, rehospitalization, or allograft failure/rejection.

181 idence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes

182 The reasons for kidney allograft failure subsequent to pancreas after kidney (P

183 g transplant are suboptimal owing to chronic allograft failure termed bronchiolitis obliterans syndro

184 ed organs had a significantly higher rate of allograft failure than locally transplanted organs in th

185 positive DSA (n=19) were more likely to have allograft failure than those without (P=0.02).

186 aimed to quantify the damage after composite allograft failure to assess whether retransplantation is

187 aving the role of elevated blood pressure in allograft failure unclear.

188 was 0.99 (+/- 0.20); mean observed/expected allograft failure was 1.03 (+/- 0.46).

189 Each independent predictor for allograft failure was assigned risk score (RS) points of

190 Maintenance immunosuppression after kidney allograft failure was associated with a greater incidenc

191 Maintenance immunosuppression after kidney allograft failure was associated with a greater incidenc

192 ospitalization with fever within 6 months of allograft failure was common, occurring in 44% of patien

193 ospitalization with fever within 6 months of allograft failure was common, occurring in 44% of patien

194 n identified that the strongest predictor of allograft failure was induction without AL (P < 0.0001).

195 hipment of organs with no HLA mismatches and allograft failure was not confirmed.

196 The risk of pancreatic allograft failure was not significantly increased.

197 edication regimens is a major cause of renal allograft failure, we evaluated the stability over time

198 death or the combined risk of death or renal allograft failure were 0.7 (95% CI, 0.1-3.8) and 0.4 (95

199 sociations of D-BMI with pancreas and kidney allograft failure were assessed by multivariate Cox regr

200 Results for death as well as death or allograft failure were generally consistent among elderl

201 Seven independent risk factors for allograft failure were identified: older recipient (haza

202 The clinical presentation was renal allograft failure, which eventually reversed.

203 fidence intervals [CI], 1.83-3.47; P<0.001), allograft failure with death-censored (HR, 3.17; 95% CI,

204 The adjusted rate ratio for allograft failure with induction therapy compared with c

205 The observed risk of allograft failure with right-sided LDN was 3.8% vs. 2.5%

206 However, the low observed risk of allograft failure with right-sided nephrectomy suggests

207 We examined the risks for DGF and allograft failure within 19,461 recipient pairs of the s

208 5 ratios > or = 15 were highly predictive of allograft failure within 6 months of the assay.

209 The primary outcome was allograft failure within 90 days.